Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Immuneering (IMRX) Non-cash Items (2021 - 2022)

Immuneering's Non-cash Items history spans 2 years, with the latest figure at $2.7 million for Q4 2022.

On a quarterly basis, Non-cash Items fell 90.17% to $2.7 million in Q4 2022 year-over-year; TTM through Dec 2022 was $2.7 million, a 90.17% decrease, with the full-year FY2022 number at $2.7 million, down 90.17% from a year prior.
Non-cash Items came in at $2.7 million for Q4 2022, down from $25.9 million in the prior quarter.
The five-year high for Non-cash Items was $56.3 million in Q3 2021, with the low at $2.7 million in Q4 2022.